Form 4: GE HealthCare Director H. Lawrence Culp Jr. Boosts Equity Holdings Through Compensation Awards

GE HealthCare Technologies Inc. Director H. Lawrence Culp Jr. reported the acquisition of 6,675 shares of common stock on May 28, 2025, through restricted stock unit and deferred stock unit awards, increasing his direct and indirect beneficial ownership.

Summary

• H. Lawrence Culp Jr., a Director of GE HealthCare Technologies Inc. (GEHC), acquired a total of 6,675 shares of common stock on May 28, 2025, through equity awards.
• This acquisition included 3,092 restricted stock units (RSUs) and 3,583 fully vested deferred stock units (DSUs).
• The RSUs are set to vest 100% on the earlier of GE HealthCare's next annual meeting of stockholders or May 28, 2026.
• The DSUs were received by Mr. Culp in lieu of 100% of his cash retainer, in accordance with GE HealthCare's Non-Employee Director Compensation and Benefits Plan.
• Following these transactions, Mr. Culp's direct beneficial ownership stands at 49,790 shares of common stock.
• His indirect beneficial ownership includes 291,177 shares held by family trusts and 70,402 shares held by a holding company.
• A previous transfer of 289,906 shares of GE HealthCare common stock to a family trust by the reporting person occurred on September 23, 2024.

Sentiment

Score: 7

Explanation: The filing indicates a director increasing their equity stake through compensation awards, which is generally a positive signal of alignment and confidence. The election to take equity over cash for a retainer is particularly positive, suggesting strong belief in the company's future.

Positives

• Director H. Lawrence Culp Jr. increased his equity stake in GE HealthCare through RSU and DSU awards, which aligns his interests with those of shareholders.
• The election to receive fully vested deferred stock units in lieu of a cash retainer demonstrates a strong commitment to long-term equity ownership and confidence in the company's future by a key director.

Negatives

• No explicit negatives are present in this Form 4 filing, as it primarily reports a standard insider equity compensation transaction.

Risks

• No specific risks are detailed in this Form 4 filing, which is a routine report of insider transactions and beneficial ownership.

Future Outlook

The vesting schedule for the restricted stock units indicates future equity settlement for the director, with 100% vesting by May 28, 2026, or the next annual meeting, aligning future compensation with company performance and providing a long-term incentive.

Management Comments

• "Each restricted stock unit and deferred stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock."
• "Settlement of vested restricted stock units may be deferred by the reporting person, in which case, settlement will occur pursuant to the reporting person's applicable deferral election in accordance with GE HealthCare's Non-Employee Director Compensation and Benefits Plan."
• "The reporting person elected, in accordance with the Plan, to receive fully vested deferred stock units in lieu of 100% of the cash retainer awarded to the reporting person."

Industry Context

This Form 4 filing reflects a standard practice of executive and director compensation through equity awards, common across industries, particularly in healthcare technology, to incentivize long-term performance and align management interests with shareholders. The election to receive deferred stock units instead of cash for a retainer is a strong signal of confidence in the company's future, often seen in companies with strong growth prospects.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Deferred Stock Units (DSUs) for director compensation is a common practice among large-cap companies, including peers like Siemens Healthineers AG (SHL.DE) and Philips (PHG), as it aligns director incentives with long-term shareholder value.
• The election by Director Culp to receive equity (DSUs) in lieu of a cash retainer is a positive signal, often seen in companies where leadership has strong conviction in future stock performance, similar to practices observed at highly successful tech and healthcare firms that prioritize equity-based compensation.

Stakeholder Impact

• Shareholders: Increased alignment of a key director's interests with shareholder value through increased equity ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Settlement of vested restricted stock units will occur pursuant to the reporting person's applicable deferral election.
• The restricted stock units will vest 100% on the earlier of GE HealthCare's next annual meeting of stockholders or May 28, 2026.

Key Dates

Recommendation

Keywords

GE HealthCare Technologies Inc., GEHC, Form 4, Insider Transaction, Restricted Stock Units, Deferred Stock Units, Director Compensation, Equity Awards, H. Lawrence Culp Jr.